Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
P2RY11 Biologics Sequence Review Report 2026: P2Y purinoceptor 11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
P2RY10 Biologics Sequence Review Report 2026: Putative P2Y purinoceptor 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
P2RY6 Biologics Sequence Review Report 2026: P2Y purinoceptor 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RY1 Biologics Sequence Review Report 2026: P2Y purinoceptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX7 Biologics Sequence Review Report 2026: P2X purinoceptor 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX5 Biologics Sequence Review Report 2026: P2X purinoceptor 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX4 Biologics Sequence Review Report 2026: P2X purinoceptor 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX3 Biologics Sequence Review Report 2026: P2X purinoceptor 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX2 Biologics Sequence Review Report 2026: P2X purinoceptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
P2RX1 Biologics Sequence Review Report 2026: P2X purinoceptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
OXER1 Biologics Sequence Review Report 2026: Oxoeicosanoid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OXER1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
NTF4 Biologics Sequence Review Report 2026: Neurotrophin-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NTF4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
230
231
232
233
234
>>
2260
>